Lipoprotein(a) was a key focus. First, the 2018 US Cholesterol Guidelines incorporated elevated lipoprotein(a) as a marker of cardiovascular risk. Second, a Latebreaker session showed a favourable benefit versus risk profile for a novel antisense oligonucleotide specific to the apolipoprotein(a) component of lipoprotein(a).
Now the stage is truly set to test the ‘lipoprotein(a) hypothesis’ with a phase III trial to evaluate whether lowering elevated lipoprotein(a) levels reduces cardiovascular events.
Henry Ginsberg What’s new on the horizon for lipoprotein(a) therapies?
Steve Nicholls Should ACS patients start a PCSK9 inhibitor in hospital?
Steve Nicholls APOLLO trial with SLN360
Tycho Tromp What can we learn from the Homozygous Familial Hypercholesterolaemia International Clinical Collaboration registry?
« Back to videos